Novo Nordisk Insulin - Search News

Novo Nordisk shares drop

Novo Nordisk says trial with next-gen drug in diabetics shows 15.7% weight loss

Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 diabetes cut their weight by 15.7% after 68 weeks. The data is seen as crucial for the future potential for its experimental next-generation obesity drug,

STAT · 4d

Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that fell short of investors’ expectations.

Markets Insider · 4d

Novo Nordisk under pressure as obesity drug disappoints in diabetes trial

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Novo Nordisk Skeptic Finally Upgrades Stock

Bloomberg L.P. · 1d

Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak

A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock.

Markets Insider · 23h

Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after

Seeking Alpha on MSN · 1d

Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last

Novo Nordisk (NVO) ended a five-day losing streak on Thursday after Kepler Cheuvreux, a long-time skeptic of the Danish biotech, finally issued a bullish rating on the maker of hugely popular obesity/ diabetes drugs,

Fierce Pharma4d

Novo Nordisk invites people with Type 2 diabetes into their ‘Ozempic Eras’ in star-studded campaign

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J

Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...

Novo Nordisk foundation’s obesity head works as paid adviser to chocolate maker Ferrero

Professor Arne Astrup is also involved in project to change widely-accepted definition of ultra-processed food ...

10d

Novo Nordisk, Sanofi Face South Africa Insulin Antitrust Probe

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market.

Medical Dialogues7h

CagriSema demonstrates superior weight loss in adults with obesity, type 2 diabetes in REDEFINE 2 trial: Novo Nordisk

Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results